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Ischemia reperfusion (IR) injury occurs when blood supply, perfusion, and concomitant reoxygenation is restored to an organ or area fol-
lowing an initial poor blood supply after a critical time period. Ischemia reperfusion injury contributes to mortality andmorbidity in many
pathological conditions in emergency medicine clinical practice, including trauma, ischemic stroke, myocardial infarction, and post-car-
diac arrest syndrome. The process of IR is multifactorial, and its pathogenesis involves several mechanisms. Reactive oxygen species
are considered key molecules in reperfusion injury due to their potent oxidizing and reducing effects that directly damage cellular mem-
branes by lipid peroxidation. In general, IR injury to an individual organ causes various pro-inflammatory mediators to be released,
which could then induce inflammation in remote organs, thereby possibly advancing the dysfunction of multiple organs. In this review,
we summarize IR injury in emergency medicine. Potential therapies include pharmacological treatment, ischemic preconditioning, and
the use of medical gases or vitamin therapy, which could significantly help experts develop strategies to inhibit IR injury.
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INTRODUCTION
WHEN AN ORGAN or area of tissue is deprived of itsblood supply, return of blood flow to the ischemic
area is essential to prevent irreversible tissue necrosis and
secure organ function. However, following this return of
perfusion and concomitant reoxygenation, a paradoxical tis-
sue response marked by initial inhibition of blood supply to
an organ can happen. Such a pathological condition is
known as ischemia and reperfusion (IR) injury and has been
a focal point for clinical and basic research.1 Ischemia reper-
fusion injury augments pathologies in many conditions in
the field of emergency medicine, including hemorrhagic
shock and resuscitation, acute coronary syndrome, usage of
surgical tourniquet, limb injury, and cerebral ischemia.
In this review, we aim to explain the pathophysiology of
IR injury, which could provide emergency physicians with a
strong basis for the investigation of novel therapeutic strate-
gies for overwhelming IR injury-induced organ damage. We
also summarize existing and possible approaches to the
treatment of IR injury that have evolved from emergency/
critical care medicine research. Although regional IR injury
to a single organ is emphasized, we also discuss other condi-
tions such as systemic reduction of perfusion and resuscita-
tion that share similar pathophysiological mechanisms in
emergency medicine.
MECHANISMS OF IR INJURY
ALTHOUGH THE COMPREHENSIVE mechanisms ofIR injury remain to be fully expounded, they can gen-
erally be divided into two different states: the ischemic state
and the reperfusion state (Fig 1).1
Ischemic state
The primary function of mitochondria is generation of ade-
nosine triphosphate (ATP) through oxidative phosphoryla-
tion. Inhibition of oxidative phosphorylation, as it occurs
during ischemia, leads to impairment of normal function.
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In the mitochondria, the ischemic state induces anaerobic
metabolism and electron transport chain dysfunction, lead-
ing to less ATP production. Decreased ATP production
results in the dysfunction of Na+-K+-ATPase, resulting in
increased intracellular calcium, hydrogen, and sodium, lead-
ing to the swelling of cells and impairment of cytoplasmic
enzyme activity. An overload of calcium damages cells
through multiple factors, destroying cell membranes, spark-
ing cell apoptosis, and hampering mitochondrial function.2
Another mechanism implicated in the pathophysiology of
ischemic injury is restriction of oxygen-sensing prolyl
hydroxylase enzymes due to their need for oxygen as a
cofactor. Hypoxia-triggered restraint of prolyl hydroxylase
enzymes promotes the post-translational activation of
hypoxia and inflammatory signaling cascades, which subse-
quently regulates the stability of the transcription factors
nuclear factor-jB (NF-jB) and hypoxia-inducible factor.
Thus, modifications in the transcriptional control of gene
expression also happen during the ischemic period.
Reperfusion state
In the reperfusion state, mitochondrial damage and elec-
trolyte imbalance result in the generation of huge amounts
of reactive oxygen species (ROS) from various sources
within minutes, including upregulation of the enzymes xan-
thine oxidase, nicotinamide adenine dinucleotide phosphate
oxidase (NOX), cyclooxygenase, lipoxygenase, and induci-
ble nitric oxide synthase (iNOS), mitochondrial electron-
transport chain reactions, and catecholamine oxidation.3
Reactive oxygen species, including peroxynitrite, super-
oxide, hydrogen peroxide, and hydroxyl radical, are mole-
cules or fragments that possess an unpaired electron.
Reactive oxygen species retention induces the destruction of
cell and organelle membranes and DNA single-strand break-
age with resultant enzyme inactivation, as well as activation
of nuclear enzyme poly (ADP-ribose) synthetase, leading to
cell death by necrosis, apoptosis, autophagy, mitoptosis, and
necroptosis.4 Lipid peroxidation, a chain reaction leading to
polyunsaturated fatty acid oxidation, subsequently disturbs
the biological membrane structure and generates toxic
metabolites like malondialdehyde.5
Ischemia reperfusion injury causes a complex of inflam-
matory immune responses without the contribution of patho-
genic triggers, a process known as sterile inflammation.
Sterile inflammation is associated with signaling events
through pattern-recognition receptors like Toll-like receptors
(TLRs), adaptive and innate immune system cell recruitment
Fig. 1. Schematic images of sequential changes in cytosolic and mitochondrial function during ischemia and reperfusion injury. During
hypoxia, reduced O2 promotes anaerobic glycolysis that generates increased cytosolic lactate leading to acidification. Increased H
+ acti-
vates Na+-H+ exchanger leading to increased cytosolic Na+, which activates Na+-Ca2+ exchanger, causing an increase in cytosolic Ca2+.
Cytosolic Ca2+ overload in turn increases mitochondrial matrix Ca2+. Impaired electron transport leads to increased generation of reac-
tive oxygen species (ROS). Impaired respiration and substrate utilization lead to decreased generation of mitochondrial adenosine
triphosphate (ATP). During reperfusion state, an increased mitochondrial permeability transition pore (mPTP) opening elevates ROS gen-
eration and disrupts intracellular distribution of Ca2+, Na+, and pH, resulting in subsequent irreversible cell death. ROS further increase
to produce even greater mitochondria damage that induces mPTP opening and release of cytochrome c that in turn triggers apoptosis.
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and activation, and complement system activation.6 Toll-like
receptor 4 is an important pattern-recognition receptor; its
mediated inflammatory response is an important function in
organ injury in the IR process.
During initiation of post-reperfusion, danger-associated
molecular patterns including peroxiredoxin, high mobility
group box-1, nucleotides, purines, and nucleic acid frag-
ments, are released and initiate inflammation. Danger-asso-
ciated molecular patterns bind innate immune receptors such
as TLRs and purinergic receptors on microglia and leuko-
cytes, leading to their activation followed by activation of
the inflammatory transcription factors NF-jB, activator pro-
tein 1, and mitogen-activated protein kinase.7,8 These mole-
cules give rise to cytokines, chemokines, adhesion
molecules (intercellular adhesion molecule-1 or E-selectin),
matrix metalloproteinase-9, iNOS, and NOX, leading to
exacerbation of ischemic injury.9 Autophagy, a cellular pro-
cess associated with damaged or unnecessary proteins and
organelle degradation, also contributes to the IR injury pro-
cess.4 The acidotic pH, although generally protective in
ischemia, is normalized following reperfusion, and this rapid
change to a normal intracellular pH level is paradoxically
thought to enhance cytotoxicity.
Systemic inflammation and remote organ
injury
Ischemia reperfusion injury primarily occurs locally, but
post-revascularization, mediators from ischemic tissue can
infiltrate the systemic circulation and influence other remote
non-ischemic organ systems. For instance, exposure of
plasma to ROS can produce chemotactic factors, which
could cause sequestration of inflammatory activations in
organs other than the initial ischemic injury site, eventually
leading to multiple organ failure.10 Systemic inflammation
evolves from a complex relationship between the primary
insult and activation of coagulation and inflammation.
ISCHEMIA REPERFUSION INJURY AND
EMERGENCY MEDICINE
IT IS CRITICAL to reduce the hypoperfusion time to pro-tect organ function. Indirect tissue injuries can be aggra-
vated by shock/resuscitation. Regarding sepsis, early
treatment with antibiotics and timely resuscitation with ade-
quate vasopressors and fluids are recommended to lessen
hypoperfusion of peripheral tissue.
Tissue/systemic hypoperfusion associated with hemor-
rhagic shock is the most common cause of preventable
trauma-related death. Resuscitative endovascular balloon
occlusion of the aorta (REBOA) has recently been used as a
different option for resuscitative thoracotomy (thoracotomy
and aortic cross-clamping) for trauma patients. Use of
REBOA is limited by substantial IR injury followed by
acute kidney disease or pulmonary edema.11 Early reperfu-
sion intervention for obstruction in the feeding vessels can
reduce cell/organ damage. Early revascularization decreases
infarct size with immediate intervention and notably results
in better long-term clinical outcomes in both cardiac ische-
mia and cerebral ischemic stroke.12 However, ischemic tis-
sue reperfusion in itself causes irreversible damage because
of IR injury. Therefore, reduction of both reperfusion-medi-
ated tissue injuries and ischemia is an important opportunity
for the development of novel treatments.
The tourniquet is the most effective and universal first-aid
device used to control hemorrhage of an injured limb in the
prehospital environment. Like in organs, acute ischemia in a
limb and return of blood flow to the extremity is a medical
emergency associated with significant morbidity and mortal-
ity.13 Ischemia reperfusion injury occurs with a variety of
surgical interventions where the blood supply is temporarily
cut off and restored, such as in organ transplantation and
coronary bypass surgery.
Post-cardiac arrest syndrome is also considered an aspect
of systemic IR injury that leads to endothelial dysfunction
with organ dysfunction, brain damage, and death.14 In car-
diac arrest, systemic ischemia results in tissue and cellular
damage by energy and oxygen store depletion. Paradoxi-
cally, reperfusion of blood to ischemic organs after success-
ful resuscitation can worsen organ damage. As highly
metabolic organs, the heart and brain are especially at risk
for these damaging effects.
Ischemia reperfusion injury is associated with endothelial
cell inflammation, higher vascular permeability, a vasodilat-
ing/vasoconstricting factor imbalance, and complement sys-
tem and coagulation activation. Endothelial dysfunction ends
in microcirculation heterogeneity and a weakened response
to endothelial-dependent vasoconstrictors and vasodilators,
resulting in hypotension. In humans, microvascular dysfunc-
tion following IR injury can result in respiratory failure pre-
senting as hypoxemia and pulmonary edema that is not
caused by heart failure but instead by disturbed alveolar–cap-
illary barrier function, leading to higher microvascular per-
meability and leakage of plasma fluid.15 Thus, multiple organ
dysfunction necessitates intensive care support.
THERAPEUTIC IR INJURY STRATEGIES
Maintenance of blood flow
OBVIOUSLY, THE MOST effective and importantstrategy to prevent IR injury is to reduce the
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hypoperfusion time. Periodic REBOA is a possible viable
adjunct to maximize survival in lethal solid organ injury
while minimizing the IR experienced with full REBOA.16
Intermittent REBOA allows titration of blood pressure while
maintaining distal organ perfusion and decreases the
ischemic burden in a severe hemorrhagic shock state. Peri-
odic REBOA could also reduce the risk of post-resuscitation
inflammatory and metabolic consequences and organ dys-
function.17
Therapeutic hypothermia
Therapeutic hypothermia has been known to reduce
ischemic brain injury.18 However, ≤30°C hypothermia was
compromised with complications including circulatory
arrest. Mild or moderate hypothermia therapy was estab-
lished that showed strong protective effects to ischemic
injury without severe complications.19 Although optimal
timing, temperature, or indication of hypothermia is still
conflicting, inducing therapeutic hypothermia has been asso-
ciated with improved neurological outcomes in post-cardiac
arrest patients.20-22 Active control of temperature (target
temperature management) is needed for post-cardiac arrest
syndrome and fever must be avoided.23
Prolonged application of tourniquets for an injured limb
can eventually result in ischemic necrosis of skeletal mus-
cles and IR injury. Regional hypothermia of 10°C on an
injured limb in a rabbit experimental model resulted in
increased ATPase activity, and decreased K+, lactate, and
inflammatory cytokine levels.24 A recent study showed that
external cooling with long-term zone 3 REBOA reduced
ischemic muscle injury and led to lower compartment pres-
sures after reperfusion in a pig model.25 The researchers
achieved external cooling by placing bags filled with ice in
both groins and wrapping the hind limbs and lower torso
with a circumferential 4°C cooling blanket during 4 h of
occlusion with zone 3 REBOA.25
Inducing a mild systemic 32–34°C hypothermia at the
start of ischemia and maintaining that hypothermia during
reperfusion conferred adequate cardioprotection in acute
myocardial IR pig and rabbit experimental models.26,27 The
neuroprotective effects of mild hypothermia were shown in
a rat ischemic brain injury model.28 However, most clinical
studies show little benefit from hypothermia in acute coro-
nary syndrome patients. An analysis of ST-segment eleva-
tion myocardial infarction patients showed that therapeutic
hypothermia induced outside the hospital (target temperature
≤35°C at reperfusion) did not improve myocardial salvage.29
Another trial was undertaken on 120 ST-segment elevation
myocardial infarction patients (<6 h) scheduled for percuta-
neous coronary intervention. Hypothermia was induced by
rapid 600–2,000 mL cold saline infusion and endovascular
cooling or standard of care. Hypothermia did not reduce
infarct size as measured on cardiac magnetic resonance
imaging.30 Of note, subgroup and meta-analyses suggest
that hypothermia’s advantages were still observable in




Delivering the potent free radical scavenger edaravone prior
to ischemic liver reperfusion reduces oxidative stress in the
reperfused liver and ensuing lung injury. Edaravone could
be advantageous for averting lung injury triggered by liver
IR.31 Using a rat model, Taniguchi et al. reported that edar-
avone decreased IR injury by diminishing oxidative stress
and reducing ensuing damaging inflammation by decreasing
expression of adhesion molecules and inflammatory cyto-
kines.32
Vitamins
There are two broad divisions of antioxidants, classified by
whether or not they are water-soluble (hydrophilic), like
ascorbic acid (vitamin C), or lipid-soluble (hydrophobic)
like b-carotene and a-tocopherol (vitamin E), which are
membrane-bound. Hydrophilic antioxidants react with blood
plasma and cell cytosol oxidants, whereas hydrophobic
antioxidants protect cell membranes against lipid peroxida-
tion.33 Scientists are investigating the role vitamin C plays
in IR injury in a growing number of clinical and preclinical
studies. The overwhelming oxidative stress that occurs dur-
ing the IR injury process can rapidly deplete the body’s vita-
min C stores because of tremendous cellular consumption.
Levels of vitamin C in the plasma are dramatically reduced
not just following cardiac arrest, but also in patients with
many other critical illnesses.34 Vitamin C impairs expression
of endothelial cell iNOS and neuronal nitric oxide syn-
thetase, thereby reducing the plasma nitric oxide (NO) level,
which causes guanylate cyclase activation, which counter-
acts vasoconstrictors’ effects. This could preserve the
baroreceptor reflex and vascular resistance and, conse-
quently, possibly maintain mean arterial pressure.35
Melatonin
Melatonin, known as a natural sedative, is a potent antioxi-
dant that is able to easily cross the blood–brain barrier and
cell membranes. In vivo, melatonin prevents slowed vascular
decompensation and the cellular energetic breakdown
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related to inflammation and IR injury mediated by inhibition
of poly (ADP-ribose) synthetase activation.36 Melatonin also
can stimulate antioxidative enzymes such as glutathione per-
oxidase, superoxide dismutase, and catalase.
Anesthesia
Commonly used anesthetic agents are known to have protec-
tive effects for IR injury. Anesthetics can penetrate the brain
parenchyma and avert oxidative neuronal injury. Several
mechanisms have been advocated, including direct and indi-
rect effects. Propofol and ketamine have properties to scav-
enge ROS and peroxynitrite and inhibit lipid peroxidation.37
Procaine and lidocaine dose-dependently eliminate H2O2
and safeguard endothelium-dependent vasorelaxation during
IR injury and against ROS attack, possibly through scaveng-
ing.38 General anesthetics slow the cellular utilization of glu-
cose and oxygen and restrain oxidative neutrophil
metabolism. Anesthetics could avoid heightening extracellu-
lar glutamate concentration and impair excitatory gluta-
matergic receptor activation that boosts oxidative stress
associated with IR injury.36
Bile pigments
Bile pigments such as biliverdin/bilirubin are produced
through heme degradation and have emerged as agents that
potently suppress IR injury in rodent models. In a rat intesti-
nal IR injury model, i.p. biliverdin injection led to a consid-
erable reduction in inflammatory cytokine mRNA
expression, reduced infiltration of neutrophils into the jeju-
nal muscularis, and averted IR-induced inhibition of intesti-
nal circular muscle contractility.39 The effects of biliverdin
have been shown in swine liver IR injury, an acknowledged
and relevant preclinical animal model. Application of bili-
verdin caused bilirubin to quickly appear in the serum and
notably quelled IR-induced liver dysfunction as determined
by multiple measurements including neutrophil infiltration,
ammonia and urea clearance, and tissue histopathology,
including hepatocyte death.40
Ischemic preconditioning
Ischemic preconditioning (IPC), a short period of ischemia
followed by brief reperfusion before a prolonged interval of
ischemia, has been reported as a sufficient operative plan to
decrease organ IR injury in clinical and experimental stud-
ies.41 Although the protective mechanism of IPC has not
been fully elucidated, it might delay the ATP depletion rate
during ischemia and ensuing ischemic episodes. Periodic
reperfusion could be advantageous to the myocardium by
flushing catabolites that accumulated during ischemia.42
Additionally, IPC escalates autophagy and decreases cellular
damage and mitochondrial dysfunction in IR injury.
Ischemic preconditioning increased expression of stress-re-
sponsive antioxidant enzymes such as heme oxygenase-1,
which is greatly induced during the oxidative stress
response, including IR conditions.43 Although these experi-
mental studies have shown some benefit, the effects of IPC
have been controversial in the clinical setting. The discrep-
ancy could be explained by the IPC protocol or severity of
IR injury.44
Remote ischemic conditioning (RIC) is also a known
promising strategy to prevent IR injury in several experi-
mental and clinical models.45 In RIC, reversible short-term
ischemia with reperfusion in one organ, tissue, or vascular
bed confers remote tissue/organ resistance to IR injury. For
example, brief ischemic episodes with intermittent reperfu-
sion are introduced in a limb, leading to systemic protection
against subsequent insults to the kidney, heart, liver, and
other tissues.46 Although the mechanisms of RIC have not
been fully elucidated, a protective signal is sent from the
RIC site to target organs, which might involve systemic,
neuronal, and humoral mechanisms. Various transmitting
routes instigate many signaling cascades, including the sur-
vivor activating factor enhancement and reperfusion injury
salvage kinase pathways.45 Protection is partially mediated
by stromal-derived factor-1a, plasma-derived dialysate and
NO, and microribonucleic acid-144 (Table 1).47 A system-
atic meta-analysis and review indicated that RIC improved
the myocardial salvage index and myocardial infarct size
after coronary intervention without mortality benefit.48
Therapeutic medical gas
Recent clinical and experimental evidence showed that a
number of gaseous molecules have significant physiological
regulatory factors with anti-inflammatory, anti-apoptotic,
and antioxidant protective effects on organs and cells.49-52
The use of medical gases for oxidative stress therapy is an
evolving possibility. Medical gases can be given directly to
patients by inhalation using a nasal cannula, ventilator cir-
cuit, and face mask.
Ischemia reperfusion injury has been treated using several
therapeutic gases, including hydrogen (H2), hydrogen sul-
fide (H2S), NO, and carbon monoxide (CO).
50,51 Carbon
monoxide, one of the byproducts of the heme oxygenase
system, can provide cytoprotection by modulating intracel-
lular signaling pathways through its vasodilative and anti-
apoptotic, anti-inflammatory, antithrombotic, and antiprolif-
erative properties.53-55 The protective results of CO for IR
injury have been extensively studied in experimental/clinical
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models. Carbon monoxide leads to vascular dilation through
activation of soluble guanylyl cyclase and inhibits pro-in-
flammatory signaling cascades. As high concentrations of
CO are known to be harmful, the optimal and secure use of
gaseous CO needs to be undertaken carefully. Carbon
monoxide-releasing molecules, which can exert various
pharmacological actions through release of controlled quan-
tities of CO in biological systems, are currently being stud-
ied to tailor therapeutic strategies to prevent IR injury.56
Endothelial NO synthase continuously generates the sol-
uble gas NO in endothelial cells. Nitric oxide regulates
endothelial function and basal vascular tone and supports
blood oxygenation. Numerous studies have suggested
endogenous NO production or its therapeutic use to attenu-
ate IR injury. Nitric oxide prevents creation of hydroxyl rad-
icals by impeding the main iron catalyst in the Fenton
reaction.57 Furthermore, NO and iron react to form an iron–
nitrosyl complex, hindering the catalytic functions of iron in
the Fenton reaction.52 Nitric oxide prompts soluble guany-
late cyclase and boosts vascular smooth muscle cell cyclic
guanosine monophosphate, resulting in vasodilation and
relaxation of vascular tone. Thus, NO actions on blood ves-
sels can enhance tissue blood supply and diminish the
inflammatory response by restraining P-selectin expression
and leukocyte recruitment, leading to safeguarding the tis-
sues from IR injury.58 Nitric oxide could be linked to both
toxic and protective effects following oxidative insults,
depending on the environment, NO levels and source, and
timing of NO administration, suggesting a brief window for
NO treatment of IR injury.52 Despite scarce high-quality
clinical research, a wealth of current evidence suggests that
use of NO-donor agents could be an effective therapy for IR
injury in humans.59
Hydrogen is a highly diffusible and flammable gas pro-
duced by bacteria in the human intestine. Although it seems
like an important biological molecule with anti-apoptotic,
anti-inflammatory, and antioxidant effects, the precise mech-
anisms of H2 remain puzzling. In a rat brain focal IR injury
model, mitochondrial ROS production was shown to induce
the mitochondrial permeability transition pore, resulting in
mitochondrial swelling, rupture, and cytochrome c release,
and finally apoptosis.60 Inhaled hydrogen therapy for lung
transplant recipients can avoid lung IR injury and markedly
improve lung graft function after lengthy cold preservation,
transplant, and reperfusion.61
Hydrogen sulfide is made endogenously from L-cysteine,
a food-derived methionine product, by cystathionine-c-lyase
and cystathionine b-synthase. Therapeutic effects of H2S
have been reported in animal IR injury models. In rodents,
H2S can trigger a reversible hypothermic and suspended-ani-
mation-like state, and H2S treatment reversibly lowers car-
diovascular function without affecting blood pressure.
Hydrogen sulfide’s impact on cytochrome c oxidase and
mitochondrial functions can explain some of its antioxidant
effects; its effects on gene expression could be associated
with actions on the NF-jB and extracellular signal-regulated
kinase pathways.62
Interestingly, combined hydrogen/CO therapy showed
improved therapeutic efficacy through both anti-inflamma-
tory and antioxidant mechanisms and could be a clinically
feasible strategy to prevent myocardial cold IR injury.63
CONCLUSION
RECENT PATHOPHYSIOLOGICAL CONCEPTS andtherapeutic strategies for overwhelming IR injury-in-
duced organ damage or systemic inflammation in emergency
medicine/critical care were summarized with a comprehen-
sive review of published works. This review provides emer-
gency physicians with a strong basis for the investigation of
novel therapeutic strategies including pharmacological
Table 1. Reported humoral mechanism of cytoprotection


























Mammalian target of rapamycin
Akt, protein kinase B; RIP, receptor-interacting protein.
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treatment, ischemic preconditioning, and the use of medical
gases or vitamin therapy, which could significantly help
experts develop strategies to inhibit IR injury.
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